Integrative care is at the heart of Shockwave use in therapy. Extracorporeal shockwave therapy (ESWT) was never meant to be a stand-alone treatment or simply an additional treatment tool. It’s part of a broader recovery strategy that must account for tissue irritability, tissue workload, physical demands, recovery timing, and progressive loading. This is not news to many clinicians who know that, like any therapy, ESWT is only as good as the overall rehabilitation plan for each patient. Experienced clinicians know the difference ESWT makes in their patients’ recovery. They’ve witnessed its impact on patient recovery firsthand, and it’s shifted mindsets from simply considering how to use the tool, e.g. selecting usage settings, to understanding that ESWT has the ability to play a critical role in rehabilitation. It’s leading clinicians to more nuanced conversations around where patients are in the load-recovery cycle and how ESWT can safely move them to the next stage of recovery.
Scientific study after scientific study continues to lay bare the data and reinforce the growing consensus among clinicians that ESWT can play a larger role in recovery. What’s been missing for some is global unanimity on technical guidance for the device. Now, The British Journal of Sports Medicine has published a modified Delphi study which sought to establish expert consensus on ESWT, including terminology, procedural considerations, parameters, and contraindications. What the study shared was not just technical guidance, but a global through-line that reiterates what many clinicians already knew: the differentiator between average and outstanding outcomes for patients is not using ESWT as a protocol-driven modality but as a strategic tool for guiding progression in recovery.
Shifting Use From Protocol-Driven to Phase-Driven
All good clinicians start with a technical understanding of modalities and how to use them to improve patient outcomes. What differentiates patient outcomes is how the clinicians think about and implement those modalities. ESWT is no exception. In fact, the BJSM study proves that ESWT may be the rule.
Research continues to validate patient improvements when ESWT is incorporated into a care plan, but there’s a difference between improved results and optimal recovery. All that’s required is a shift in how clinicians consider ESWT. Instead of integrating ESWT based solely on a diagnosis, the study indicates optimal results come from integrating ESWT based on what the tissue can tolerate and how ESWT can help it tolerate more over time. ESWT is most effective when combined with mechanical loading strategies rather than as an isolated modality. From a load-management perspective, ESWT can be thought of as a way to create a window of opportunity by reducing pain and influencing tissue biology so that the patient can better tolerate the right load at the right time. Clinicians need a thorough loading progression plan combined with the window ESWT creates to avoid under-dosing rehab or overloading irritable tissue. This is where the shift from thinking of ESWT in terms of an add-on tool to a stepping stone for the next phase of care comes into play.
Sequencing Not Just Settings
Rather than just focusing on which tissue is irritated and which settings match a protocol, decision-making for treatment should center on what load the tissue can tolerate today and how ESWT can help it tolerate a little more tomorrow. Consider the following examples and how the use of ESWT acts as an adjunct to help progress between phases of care.
1. High Irritability Presentation
In high‑irritability presentations like acute reactive tendinopathy or severe plantar heel pain, the priority is symptom modulation and threat reduction, not capacity building. The goal is to calm the system so the tissue becomes less reactive and more tolerant of gentle input. A lower dose of ESWT as a tolerance-focused intervention works to help calm symptoms, with parameters chosen to emphasize pain relief and the patient’s comfort. The goal is to reduce the perceived threat so the patient can tolerate low-level mechanical loading such as isometrics and graded weight bearing, safely. The key to successfully utilizing ESWT to move the patient to the next phase of recovery is considering load progression. In high-irritability presentations, clinicians should base decisions on how the tissue responds over the next 24-48 hours and not just on in-session improvements.
2. Moderate Irritability Presentation
Cases of mid-stage tendinopathy, persistent plantar fasciopathy, and other moderate irritability presentations require a different approach when integrating ESWT into the recovery plan. The focus shifts toward building tolerance to progressively higher loads while keeping symptoms stable and predictable. In these scenarios, it’s easy to see how ESWT integrates into a structured loading program as a true complement to a program rather than a stand-alone solution. Implemented with slow, heavy loading, tempo manipulation, and progress energy-storage tasks, ESWT helps to create an opportunity at each stage of progression that can yield greater improvements in pain reduction and tissue function. The load strategy is guided by tangible symptom response and function. Objective measures, e.g. single calf capacity, fill the window created by ESWT.
3. Low Irritability / Return-to-Performance Phase for Athletes
The focus for low-irritability patients or return-to-performance athletes becomes integrating ESWT around training, competition, and tissue resilience, not just pain elimination. Many of these patients may experience lingering tissue sensitivity but experience minimal day-to-day symptoms. ESWT can be strategically placed around training blocks, lifting sessions, or competitions to help manage residual symptoms, stiffness, or perceived tightness, without becoming the focus of care. The load strategy centers on high‑quality, sport‑specific loading, deceleration, and energy‑storage work, and conditioning that mirrors competition demands. The guiding question becomes: “How can ESWT help this athlete tolerate the planned training spike or competition stress without drifting back into high irritability?” In this phase, shockwave functions as a recovery and fine‑tuning tool that helps maintain tissue tolerance so the athlete can consistently hit the loads required for full return to performance.
4. Chronic Tendon Presentation
In chronic tendon and recalcitrant presentations, durable change depends on progressive mechanical loading and remodeling, not endless symptom chasing. These are the patients who feel they have tried everything. ESWT should be positioned as an adjunctive tool that helps patients tolerate the key ingredients of an evidence‑based loading plan: heavy isometrics, slow heavy resistance, and later, plyometric or energy‑storage work. Relying on ESWT as passive stand‑alone care may provide temporary symptom relief but rarely delivers meaningful or lasting improvements in tissue capacity. A more deliberate strategy is to clearly map out loading phases and then align ESWT blocks with each phase, ensuring every treatment sits in service of a specific functional step. This keeps shockwave anchored to progression rather than repetition, converting symptom change into long‑term improvements in tendon resilience and capacity.
Across all of these scenarios, the key is not to consider the patient’s irritability and capacity, the next step in load, and how ESWT can help them tolerate that step. It’s not simply treating the tissue.
The True Value of Shockwave
The value of a Shockwave isn’t just the device itself. It’s in understanding how to sequence it intelligently within a rehabilitation care plan. It’s a shift in clinicians asking themselves, “which protocol should I run for X diagnosis?” And toward “how do I integrate ESWT so I don’t undergo rehab, overload irritated tissue, or treat in isolation without a progression strategy?” ESWT isn’t a stand-alone tool or treatment modality; it’s designed to not only to treat symptoms but also to help create an overall more effective treatment plan by opening safe windows of tolerance to move patients forward on their recovery path.
This new ESWT consensus doesn’t just validate Shockwave’s use as an integrative care tool; it formalizes it. Shockwave is at its best when it sits inside a thoughtful load‑management plan, not above it. The differentiator in outcomes is not the right settings. It is knowing how to read tissue irritability, match it to the right loading phase, and use ESWT to safely bridge the gap to the next step in capacity.
Shockwave use should feel less like running a protocol and more like solving a sequencing problem. The real value of ESWT is not in what it does to the tissue in isolation, but in the windows of tolerance it creates for better rehab. When clinicians anchor their decisions to assessing what the tissue can tolerate now and how ESWT can help it tolerate in the future, they reduce the risk of under‑dosing rehab and avoid overloading irritable structures. They stop treating in isolation from progression strategy. Shockwave becomes a catalyst for smarter, more intentional rehabilitation. Not a shortcut.
This consensus invites clinicians to see ESWT as an integrative tool that sharpens clinical reasoning rather than replacing it. By continually framing treatment around irritability, capacity, and the next logical load step, clinicians can turn shockwave from a device they own into a strategy they master.
Our teams are here to help you make the most of your Shockwave device to advance patient care thoughtfully. Contact us at (770)612-8245 or info@kinasmedical.com
——
This blog post is based on TBJSM Delphi Study: https://bjsm.bmj.com/content/59/18/1287;